Xenon Pharmaceuticals Conference Call Summary Company Overview - **Company**: Xenon Pharmaceuticals (NasdaqGM:XENE) - **Focus**: Development of innovative therapies for epilepsy, psychiatry, and pain management Key Themes Discussed 1. **Lead Program - Azetukalner in Epilepsy** - Near-term phase 3 data expected in early 2026 from the fully enrolled EXTOL-two program [2][4] - Positive phase 2b data showing best efficacy in focal onset seizure studies with a severe patient population [6][7] - High confidence in phase 3 readout due to consistent inclusion-exclusion criteria and experienced clinical sites [10][11] 2. **Expansion into Psychiatry** - Ongoing phase 3 trials for major depressive disorder (MDD) and recently initiated trials for bipolar depression [2][3] - Phase 2 proof of concept study (ExNOVA) showed clear separation between active and placebo with a three-point difference on clinical scales [25][26] 3. **Emerging Early-Stage Portfolio in Pain** - Two phase 1 assets targeting NaV1.7 and Kv7, with plans to advance to phase 2 proof of concept studies in 2026 [3][50] - NaV1.7 target based on genetic studies showing patients with loss of function do not feel pain [36][37] Important Data and Insights - **Azetukalner Efficacy**: Placebo-adjusted efficacy in phase 2b ranged from teens to low 30s in monthly seizure reduction [9] - **Commercial Strategy**: Engaging with the epilepsy community and preparing for a successful launch with a Chief Commercial Officer and medical science liaisons in place [14][16] - **Market Opportunity**: Approximately 1 million patients in the U.S. with focal onset seizures are not achieving good seizure control [18] Competitive Landscape - **Market Dynamics**: Acknowledgment of multiple existing drugs in the focal onset seizure market, but belief in the unique profile of Azetukalner to differentiate from competitors [34][35] - **Regulatory Path**: Plans to file NDA next year, with Exfil and Exfil II studies included in the filing package [12][13] Pipeline Developments 1. **NaV1.7 and Kv7 Programs** - NaV1.7 in phase I study with a focus on achieving high receptor occupancy and safety [39][40] - Kv7 program showing potential analgesic effects similar to opioids [50] 2. **NaV1.1 for Dravet Syndrome** - Development of an oral small molecule to potentiate NaV1.1 channels, aiming to protect against seizures and improve survival in animal models [51][53] - Plans to initiate human clinical trials next year [54] Financial Position - **Cash Reserves**: Over $500 million in cash at the end of the last quarter, expected to sustain operations into 2027 [55]

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: Conference Call/Webcast Information: | Date: | Monday, August 11, 2025 | | --- | --- | | Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) | | Webcast: | Pre-register here | | Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers | | Conference ID: | 4102397 | A live webcast of the company prese ...

Core Points - Xenon Pharmaceuticals Inc. has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution effective June 27, 2025 [1] - The Russell 3000® Index tracks the performance of the largest 3,000 U.S. stocks by market capitalization, while the Russell 2000® Index measures the performance of the 2,000 smallest companies within the Russell 3000® Index [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. indexes, making them widely used by investment managers and institutional investors [3] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics [4] - The company is advancing an ion channel product portfolio to address high unmet medical needs, including epilepsy and depression [4] - Azetukalner, a novel and highly potent selective Kv7 potassium channel opener, is the most advanced clinically validated potassium channel modulator in late-stage clinical development for multiple indications [4]

Company Overview - Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need [2] - The company is advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression [2] - Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, is the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications [2] Event Announcement - Xenon Pharmaceuticals will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL, from June 9-11, 2025 [1] - The fireside chat presentation is scheduled for June 10, 2025, from 3:20-3:55 PM Eastern Time, with Ian Mortimer, President and CEO, as the presenter [1] - A live audio webcast of the presentation will be available on the "Investors" section of Xenon's website and will be posted for replay following the event [1]

Company Overview - Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need [3] - The company is advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression [3] - Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, is highlighted as the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications [3] Event Participation - Xenon Pharmaceuticals will present at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY, on May 20-21, 2025 [1] - The presentation will take place on May 21, 2025, from 10:30-10:55 AM Eastern Time, featuring Ian Mortimer, President and Chief Executive Officer [2] - A live audio webcast of the presentation will be available on the "Investors" section of Xenon's website and will be posted for replay following the event [2]

Core Viewpoint - Xenon Pharmaceuticals Inc. is set to report its first quarter 2025 financial results and provide a business update on May 12, 2025, after the U.S. financial markets close [1]. Group 1: Financial Reporting - The financial results and business update will be announced after the close of U.S. financial markets on May 12, 2025 [1]. - A conference call and webcast will take place on the same day at 4:30 pm Eastern Time [2]. Group 2: Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for conditions such as epilepsy and depression [3]. - The company is advancing an ion channel product portfolio, with Azetukalner being the most advanced potassium channel modulator in late-stage clinical development [3].